Tamoxifen and Cyproterone Acetate in Pancreatic Cancer
Author Information
Author(s): J.J. Keating, P.J. Johnson, A.M.G. Cochrane, B.G. Gazzard, N. Krasner, P.M. Smith, P.N. Trewby, P. Wheeler, S.P. Wilkinson, R. Williams
Primary Institution: King's College Hospital and School of Medicine & Dentistry
Hypothesis
Does treatment with tamoxifen or cyproterone acetate improve survival in patients with pancreatic adenocarcinoma compared to no treatment?
Conclusion
Tamoxifen treatment resulted in longer median survival compared to no treatment, but the difference was not statistically significant.
Supporting Evidence
- Median survival for tamoxifen was 5.25 months, compared to 4.25 months for cyproterone acetate and 3 months for no treatment.
- No side effects attributable to treatment were observed.
- Statistical analysis showed that younger age and better performance status were associated with longer survival.
Takeaway
Doctors tested two medicines to see if they help people with pancreatic cancer live longer, but they didn't find a clear answer.
Methodology
Patients were randomly assigned to receive tamoxifen, cyproterone acetate, or no treatment, and their survival was monitored.
Limitations
The study did not achieve statistical significance for the survival differences, and the sample size may limit the generalizability of the findings.
Participant Demographics
Patients included both males and females with a mean age of around 64 years.
Statistical Information
P-Value
P = 0.071 for tamoxifen, P = 0.5 for cyproterone acetate
Confidence Interval
95% confidence interval -7% to +62% for tamoxifen
Want to read the original?
Access the complete publication on the publisher's website